314 related articles for article (PubMed ID: 23888949)
1. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.
Bruegl AS; Djordjevic B; Urbauer DL; Westin SN; Soliman PT; Lu KH; Luthra R; Broaddus RR
Curr Pharm Des; 2014; 20(11):1655-63. PubMed ID: 23888949
[TBL] [Abstract][Full Text] [Related]
2. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
3. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
4. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
5. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
[TBL] [Abstract][Full Text] [Related]
7. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
[TBL] [Abstract][Full Text] [Related]
8. Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.
Walsh MD; Cummings MC; Buchanan DD; Dambacher WM; Arnold S; McKeone D; Byrnes R; Barker MA; Leggett BA; Gattas M; Jass JR; Spurdle AB; Young J; Obermair A
Clin Cancer Res; 2008 Mar; 14(6):1692-700. PubMed ID: 18310315
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
[TBL] [Abstract][Full Text] [Related]
10. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.
Walsh CS; Blum A; Walts A; Alsabeh R; Tran H; Koeffler HP; Karlan BY
Gynecol Oncol; 2010 Mar; 116(3):516-21. PubMed ID: 20034658
[TBL] [Abstract][Full Text] [Related]
12. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
[TBL] [Abstract][Full Text] [Related]
13. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
[TBL] [Abstract][Full Text] [Related]
14. Simplified identification of Lynch syndrome: a prospective, multicenter study.
Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.
Bruegl AS; Djordjevic B; Batte B; Daniels M; Fellman B; Urbauer D; Luthra R; Sun C; Lu KH; Broaddus RR
Cancer Prev Res (Phila); 2014 Jul; 7(7):686-97. PubMed ID: 24771847
[TBL] [Abstract][Full Text] [Related]
16. Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.
Bruegl AS; Kernberg A; Broaddus RR
Adv Anat Pathol; 2017 Nov; 24(6):372-378. PubMed ID: 28820751
[TBL] [Abstract][Full Text] [Related]
17. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
18. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
20. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
